^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Lung Adenocarcinoma
    Drug:Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    J Formos Med Assoc
    Title:

    Comparing survival and subsequent treatment of first-line tyrosine kinase inhibitors in patients of advanced lung adenocarcinoma with epidermal growth factor receptor mutation

    Published date:
    03/09/2021
    Excerpt:
    In this real-world data analysis with a nationwide retrospective cohort design, adult patients with newly diagnosed advanced lung adenocarcinoma with EGFR mutation...The median (95% confidence interval [CI]) OS were 24.2 (22.9-26.2), 25.7 (24.0-27.9), and 29.1 (25.8-32.1) months for those receiving gefitinib, erlotinib, and afatinib, respectively (p = 0.001).
    DOI:
    10.1016/j.jfma.2021.02.012
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    Afatinib (Giotrif) is accepted for use within NHS Scotland

    Excerpt:
    Afatinib (Giotrif) is accepted for use within NHS Scotland...as monotherapy, for the treatment of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

    Excerpt:
    ...EGFR(Epidermal Growth Factor Receptor) mutation detected by central laboratory analysis of tumor biopsy material 3....
    Trial ID:
    LUX-Lung 6
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    ADAM-Afatinib Diarrhea Assessment and Management

    Excerpt:
    ...Pathologically confirmed diagnosis of Stage IIIB or Stage IV adenocarcinoma of the lung, with EGFR mutations-positive status, who are...
    More C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Surg
    Title:

    Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA–IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study

    Published date:
    03/11/2022
    Excerpt:
    ...patients with stage II–III EGFR-mutated adenocarcinoma who underwent cancer resection surgery at a single center were enrolled....The initial EGFR TKIs were mostly gefitinib (n = 25, 83%), and others were erlotinib (n = 3, 10%) and afatinib (n = 2, 6%). The mean disease-free survival (DFS) was 53.3 months. The 2- and 5-year DFS rate was 90.0 and 73.3%, respectively….To our knowledge, this study provides the longest experience of TKI in patients with resected EGFR mutations...
    DOI:
    https://doi.org/10.3389/fsurg.2022.816018
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    BMC Cancer
    Title:

    Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

    Published date:
    01/11/2021
    Excerpt:
    Afatinib was significantly associated with a longer PFS, presenting constant effectiveness in all EGFR mutation types. 
    DOI:
    10.1186/s12885-020-07765-6